Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities - Takeaways - MDSpire

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities

  • By

  • Meng Li

  • Suping Tang

  • Peng Yang

  • Hao Zhou

  • July 15, 2026

Share

  • 1

    Drug-resistant persister cells (DTP) are crucial for understanding therapy resistance in lymphoid malignancies.

  • 2

    DTP cells arise in response to chemotherapy by adopting a quiescent state and remodeling their molecular programs.

  • 3

    DTP cells differ from genetically fixed resistant clones as they represent a transient and adaptive population.

  • 4

    Resistance mechanisms in DTP cells are primarily driven by non-genetic adaptations rather than genetic mutations.

  • 5

    Research on DTP cells may inform innovative treatment strategies and improve understanding of minimal residual disease.

Original Source(s)

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities

  • by Meng Li, Suping Tang, Peng Yang, Hao Zhou

  • July 15, 2026

Related Content

Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis

Financial distress among women with advanced or metastatic breast cancer in Germany: secondary analysis of prospective ePROCOM data of a two-center cohort

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis